Day: April 9, 2025

Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis. Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella of which 62.3 million occur in children younger than five years1. Developing an effective vaccine to prevent this deadly disease...

Mr. Morrish will be proposed for appointment to the Board at the Annual General Meeting scheduled for 9 May 2025. He is the former Managing Director and Regional Head of Europe at GIC Real Estate, where he oversaw European property investments.Antwerp, Belgium – 9 April 2025: VGP, a pan-European owner, manager and developer of high-quality logistics and industrial real estate, as well as a renewable energy provider, announces the nomination of Mr. Chris Morrish as a member of its Board of Directors. He will bring his broad experience in the real estate sector to further strengthen VGP’s Board. Mr. Morrish will be proposed for appointment to the Board at the Annual General Meeting scheduled for 9 May 2025. Mr. Chris Morrish currently is a Senior Advisor at FREO Group and previously served as Managing Director and Regional Head for Europe...

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertensionAllschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of “Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertension1. The publication reports preplanned analyses of the efficacy, tolerability and safety of aprocitentan – Idorsia’s once-daily, orally active, dual endothelin receptor antagonist – in the subgroup of African American patients enrolled in the Phase 3 PRECISION study2 in patients with confirmed resistant hypertension. Aprocitentan, when added to a combination of at least three antihypertensive drugs (four in more than 50% of patients), produced...

Amsterdam, 9 April 2025 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that the Management Board has approved a capital investment of USD $15 million to establish an aluminothermic production facility to manufacture chrome metal in the United States. The facility, with an annual capacity of up to 6,500 tons, will be located next to AMG Titanium’s facility in New Castle, Pennsylvania. We expect it to be operational in the first quarter of 2026. AMG Chrome is a major producer of chrome metal in the UK. The New Castle, Pennsylvania facility will be the only chrome metal production facility in operation within the United States. Chrome metal is deemed a Critical Material in the United States due to its importance in various industrial alloys and lack of US production. About AMG AMG’s mission...

Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on March 17, 2025), has now approved the updated label for TRYVIO™ (aprocitentan). TRYVIO is Idorsia’s dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination with other antihypertensives to lower blood pressure in patients who are not adequately controlled on other drugs. The FDA determined that a REMS was no longer necessary to ensure the benefits of TRYVIO outweigh the risk of embryo-fetal toxicity and that labeling is sufficient for conveying the safety information. Michael Moye, President and General Manager of Idorsia US, commented: “The...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, April 09, 2025 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce that, further to its news release dated April 1, 2025 and due to increased investor interest, the Company has increased the non-brokered private placement from 13,000,000 common shares (the “Shares”) to up to 14,500,000 Shares at a price of CDN$0.10 per Share for gross proceeds of up to CDN$1,450,000 (the “Offering”). Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), up to 13,500,000 Shares (the “LIFE Securities”) will be offered pursuant to the listed issuer financing...